[Biologic activity of prostacyclin in patients with malignant tumors of the bones and soft tissues].
Hemostatic diffusion is mediated in part by platelet activation. Prostacyclin (PGI2) is known to be a powerful inhibitor of the aggregation of human platelets in vitro. In this study exogenous PGI2 was incubated in plasma of patients with bone and soft tissue cancer and its inhibiting activity of platelet aggregation was evaluated. Inhibition was found to be significantly lower and of shorter duration in the plasma of the 10 cancer patients tested as compared to the activity in the plasma of the healthy controls. Mechanisms of decreased prostacyclin activity are discussed in relation to the platelets in tumor cell metastases.
Tucci
A
A
del Prete
S
S
Maione
C
C
D000293:Adolescent; D000328:Adult; D001859:Bone Neoplasms / Q000378:metabolism*; D002648:Child; D011464:Epoprostenol / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis / Q000503:physiopathology*; D010975:Platelet Aggregation Inhibitors / Q000378:metabolism*; D012983:Soft Tissue Neoplasms / Q000378:metabolism*
D010975:Platelet Aggregation Inhibitors; D011464:Epoprostenol
Attività biologica della prostaciclina in pazienti affetti da tumori maligni dell'osso e dei tessuti molli.